A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Recruiting · Phase 1, Phase 2 · NCT06158854
Conditions: Immunoglobulin Light Chain (AL) Amyloidosis
At a glance
- Research payments reported, 2025
- $655,061
- U.S. investigators named
- 13
- Sites paid
- 12
- Planned or actual enrollment
- 76
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-383 (Etentamig) (drug)
- Dates
- Started 2024-04-01; completion 2031-08
- Results posted
- Not yet
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma cells. This is a study to determine adverse events and change in disease activity in adult participants with AL amyloidosis treated with ABBV-383. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of AL amyloidosis. This study in broken into 2 parts (dose escalation and dose expansion) with 4 arms. During dose escalation (arms 1-3) participants will receive 1 of 3 doses of ABBV-383 to determine the part 2 dose. After completion of the d…
From ClinicalTrials.gov, last updated 2026-05-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $655,061 in research payments for this study in 2025 (62 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Surbhi Sidana, M.D. Hematology · Stanford, CA
- James E. Hoffman, M.D. Hematology & Oncology · Miami, FL
- Dickran G. Kazandjian, M.D. Hematology & Oncology · Miami, FL
- Vaishali Sanchorawala, M.D. Hematology · Boston, MA
- Angela Dispenzieri, M.D. Hematology · Rochester, MN
- Manisha Bhutani, MD Hematology · Charlotte, NC
- John T. Mckay, D.O. Hematology & Oncology · Winston Salem, NC
- Rajshekhar Chakraborty, MD Medical Oncology · New York, NY
- Heather J. Landau, M.D. Hematology & Oncology · New York, NY
- Eva Medvedova, M.D. Hematology · Portland, OR
- Andrew J. Cowan, M.D. Hematology & Oncology · Seattle, WA
- Danai Dima, MD Hematology & Oncology · Seattle, WA
- Anita D'souza, MD Hematology & Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Atrium Health Foundation $139,425
- University of Washington Medical Ctr, WA $82,719
- The Trustees of Columbia University $82,514
- Medical College of Wisconsin $56,792
- University of Miami $53,797
- Boston Medical Center, MA $53,786
- Mayo Clinic Rochester $49,916
- Ohsu Hospital and Clinics, OR $44,346
- Mayo Clinic $38,507
- Memorial Sloan-Kettering Cancer Ctr $24,723
- The Board of Trustees of the Leland $17,831
- $5,800
- Wake Forest University $4,905
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.